Catatan sumber primer
PenentuHasil topline
Invivyd: Data uji coba Fase 3 DECLARATION VYD2311 diharapkan pertengahan 2026
Invivyd mengumumkan bahwa data uji coba Fase 3 DECLARATION untuk VYD2311 diharapkan pertengahan 2026. Uji coba ini mengevaluasi VYD2311 untuk pencegahan COVID-19. Pendaftaran penuh telah tercapai, dan Komite Pemantau Data Independen merekomendasikan agar wanita hamil dan menyusui dapat mendaftar.
Fakta utama
- Diajukan
- 5 Mar 2026, 12.11
- Peristiwa
- Hasil topline
- Arah
- Netral
- Perusahaan
IVVDInvivyd- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
Kutipan sumber
EX-99.1 2 d118119dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates • Achieved Q4 2025 PEMGARDA ® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter • 2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025 • Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025 • DECLARATION trial on track with full enrollment achieved • DEC